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Summary 
Recent data indicate apreviously unsuspected link between the complement system and adipocyte 
biology. Murine adipocytes produce key components of the alternative pathway of complement 
and are able to activate this pathway. This suggested to us an explanation for adipose tissue loss 
in partial ipodystrophy, a rare human condition usually associated with the immunoglobulin 
G (IgG) autoantibody nephritic factor (NeF) which leads to enhanced alternative pathway activation 
in vivo. We hypothesized that in the presence of NeE there is dysregulated complement activation 
at the membrane ofthe adipocyte, l ading to adipocyte lysis. Here we show that adipocytes xplanted 
from rat epididymal fat pads are lysed by NeF-containing sera but not by control sera. A similar 
pattern is seen with IgG fractions of these sera. Adipocyte lysis in the presence of NeF is associated 
with the generation offluid-phase terminal complement complexes, the level of which correlates 
closely with the level of lactate dehydrogenase, a marker of cell lysis. Lysis is abolished by 
ethylenediaminetetraacetic dd, which chelates divalent cations and prevents complement activation, 
and reduced by an antibody to factor D, a key component of the alternative pathway. These 
data provide an explanation for the previously obscure link between NeF and fat cell damage. 
T he complement system plays an integral role in both afferent and efferent limbs of the immune response, with 
an important role in host defence (1). Complement activa- 
tion occurs either via the classical pathway, typically initi- 
ated by antigen-antibody complexes, or via the alternative 
pathway. Both pathways proceed via the third component 
of complement (C3) to a terminal pathway which leads to 
lysis of target cells. The key proteins in the alternative pathway 
are factors D and B. Factor D cleaves factor B complexed with 
activated C3 to form the alternative pathway C3 convertase, 
C3bBb. There is continuous low-level activity of the alterna- 
tive pathway in vivo; this is controlled by the regulatory pro- 
teins factors H and I and by the fact that C3bBb is unstable, 
with a half-life of around 4min in vitro (2). Nephritic factor 
(NeF) is a human autoantibody escribed originally in pa- 
tients with mesangiocapillary glomerulonephritis type II (3, 
4) but associated more consistently with the unusual condi- 
tion of partial ipodystrophy (PLD) (5). In PLD, there is loss 
of fat from the face and upper body which is usually of acute 
onset, often after a viral infection (6). It has been demon- 
strated that NeF is an IgG autoantibody to the alternative 
pathway C3 convertase, C3bBb, which it stabilizes against 
dissociation by factor H, the normal control mechanism. This 
leads to dysregulation in vivo of the alternative pathway and 
results in hypocomplementemia with low levels of C3 and 
the presence of the complement fragment C3dg in the circu- 
lation (2, 5). 
The mechanism ofthe association between this patholog- 
ical activation of the alternative pathway and partial ipodys- 
trophy has been obscure. However, the recent discovery (7, 
8) that factor D of the alternative pathway is identical to 
adipsin, a serine protease of previously unknown function 
produced by mature adipocytes, has suggested a possible mech- 
anism for the association. Adipocytes have now been shown 
to produce not only factor D, but also factor B and C3, and 
to be capable of activating the alternative pathway in vitro 
and in vivo (9). We have therefore xplored the possibility 
that in the presence of NeF this local production of comple- 
ment components and particularly of factor D may lead to 
damage to the adipocyte. We describe here in vitro experi- 
ments that show complement-mediated lysisof adipocytes 
by NeF-containing sera. Release of lactate dehydrogenase 
(LDH) was measured as a marker of adipocyte lysis (10), and 
we also quantitated the generation of terminal complement 
complexes (TCC). The level of fluid-phase TCC correlates 
closely with TCC assembly on target cells (where TCC forms 
the membrane attack complex, MAC) and provides areliable 
index of terminal complement activation (11). 
Materials and Methods 
Serum samples were collected from three patients with NeF and 
from six controls (five normal sera from healthy laboratory staff" 
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and serum from a patient with lupus nephritis and hypocom- 
plementemia asa disease control). Aliquots of fresh serum were 
frozen at - 20~ until use. IgG fractions were prepared either by 120o 
affinity chromatography on protein G or by 50% ammonium sul- 
phate precipitation. ~ooo 
Epididymal fat pads were removed from Brown Norway rats, --_ 
minced into small fragments, and digested with type II collagenase ~ s0o 
(Sigma Immunochemicals, Poole, NK) for 45 min at 37~ A single ~ 600 
cell suspension of adipocytes was obtained by sieving through a .a 
sterile nylon sieve before centrifugation at 400 g for I min. In some 2 a00 
experiments, other target cells were used: human adipocytes pre- -6 
pared in a similar way from small samples of subcutaneous fat ob- 200 
tained at routine surgery; the murine preadipocyte c ll line F442A 
(12); and rat peripheral blood mononuclear cells prepared by den- o 
sity gradient centrifugation of anticoagnlated whole blood. 
All incubations were in Medium-199 (Flow Laboratories, Irvine, 
UK), supplemented with 20 mM D-glucose (Sigma Immunochem- 
icals) and 100 mg/1 t-glutamine (Flow Laboratories), and buffered 
with 25 mM Hepes (Flow Laboratories), at37~ in a humidified 
atmosphere with 5% CO2. 800/~1 of adipocyte suspension was 
added to 2-ml wells in a tissue culture-treated plate (Corning Inc., 
Corning, NY), and incubated with 800/~l of serum (normal, dis- 
ease control, or NeF). In other experiments, a similar quantity of 
purified IgG was added, together with 400/d of normal serum 
as a source of complement components. The effects of EI~A, which 
chelates divalent cations and abolishes complement activation, and 
a mAb which binds to and blocks the function of factor D (13) 
were also examined. Positive controls were incorporated: etergent 
lysis of adipocytes using 2% Triton X-100 (Sigma Immunochem- 
icals) for maximal LDH release and a concentration f zymosan 
designed to cause maximal alternative pathway complement acti- 
vation (15 mg/ml) for TCC generation. 50-/~1 aliquots of infrana- 
tant were removed at intervals and stored at 4~ overnight before 
being assayed in one batch. All samples were coded and analyzed 
without knowledge of experimental groups. 
LDH assays were performed on an analyzer (Monarch Cen- 
trifugal; Instrumentation Laboratory, Warrington, UK) using a 
colorimetric assay based on the generation of nicotinamide adenine 
dinucleotide (NAD *) and lactate from pyruvate and NADH (14). 
TCC was assayed by sandwich ELISA as previously described 
(15). Briefly, mAb (WU 7-2) directed against a neoepitope ofTCC 
was adsorbed to microplate wells (1.5/,~g/well, overnight at 4~ 
After blocking with PBS containing 1% gelatin, wells were in- 
cubated with test samples at 1:16 and 1:80 dilutions. Biotinylated 
polyclonal goat anti-C6 IgG was then added (2.5/~g/well), fol- 
lowed by horseradish peroxidase-labeled streptavidin (Amersham 
International, Amersham, Bucks, UK) at a dilution of 1:500. Fi- 
nally, 2,2'-azino-di-(3-ethylbenzthiazoline) sulfonic acid (Sigma Im- 
munochemicals) was added and the increase in absorption at 410 2o 
nm was recorded using an automated ELISA plate reader (Bio-Rad 
Laboratories, Hemel Hempstead, UK). The data were related to 
a standard curve calibrated using a standard complement-activated 
serum with a known concentration of TCC. 
Results 
Incubation of rat epididymal fat pad cells with NeF- 
containing sera was consistently associated with progressive 
LDH releases over 20 h, whereas incubation with control 
sera was associated with little or no rise in LDH (Fig. 1: 
results for two NeF sera. We have recently tested athird NeF 
serum, and this gave a similar pattern of LDH release). By 
Normal NeF1 
[ ]  time 0 
[ ]  sr~ 
[ ]  2o~ 
NeF2 
Figure 1. LDH actavity (expressed as elta LDH, i.e., change from base- 
line level) with time in infranatants from incubations ofadipocytes with 
one normal and two NeF sen. Data shown is representative of eight similar 
experiments in which the two NeF sera nd six control sera were tested. 
20 h, the level of LDH in the incubations with NeF sera 
approached that seen when ceils were totally lysed with de- 
tergent. IgG fractions of the sera gave a similar pattern (data 
not shown). There was a similar effect on human adipocytes, 
but rat lymphocytes and the routine preadipocyte call line 
F442A were not affected, so that there was no evidence of 
a nonspecific toxic effect (data not shown). NeF sera con- 
tained only low levels of TCC initially, but TCC levels rose 
progressively with time during incubation with adipocytes. 
There was a smaller ise in TCC with normal sera (Fig. 2). 
TCC levels correlated osdy with LDH release in incuba- 
tions with NeF sera, but with normal sera there was no corre- 
lation (Fig. 3). When zymosan was used to cause maximal 
complement activation, high levels of TCC were produced, 
but no rise in LDH occurred (data not shown). LDH release 
from adipocytes after incubation with NeF sera was abol- 
ished by coincubation with EDTA, and was reduced by coin- 
cubation with an anti-factor D mAb (Fig. 4). 
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Figure 2. TCC measurements (expressed as elta TCC, Le., change from 
baseline l vel) with time from same mfranatants a  m Fig. 1. 
1828 Complement-me&areal Adipocyte Lysis by Nephritic Factor Sera 
100 9 
0 
0 
I-. 60 -  
,5 
~ 60-  
'~ 40 '  
E 2o. 
X 
[] 
i 
A 
A 
20 40 60 80 
Normalized change in LDH 
f 
100 
100 9 
0 
0 
I-- 80.  
._= 
=geo 
o 
Z 
lO0 . 
o 
0 
I'- 80" 
@ 
~ eo 
, o  
Z 
[ • ]  9 9 am 
r=0.65 / r  
p = O . ~  ,, 
M ~ . /  -- I I  9 9 9 
i i i , i 
20 40 60 80 100 
Normal ized change in LDH 
IN 
r=0.73 . 
lx,~ i i , j 
20 40 60 80 100 
Normalized change in LDH 
Figure 3. Scatterplot relating 
changes in LDH and TCC. Data 
pooled from the four experiments 
in which LDH and TCC were both 
measured, normalized by expressing 
maximum change from baseline in
each experiment as100% and all 
other esults as percentage of this. 
Data shown for one normal serum 
(A; no significant correlation) and 
two NeF sera (B and C; Pearson's 
r as indicated). Other control sera 
also showed no significant corre- 
lation. 
Discuss ion  
These data indicate that NeF-containing sera lead to adipo- 
cyte lysis by a complement-dependent mechanism. This may 
explain the long-standing mystery of the link between NeF 
and PLD. We postulate that local production of factor D and 
other complement components by the adipocyte becomes del- 
eterious in the presence of NeF, which deregulates the alter- 
native pathway. Baseline levels of TCC in the NeF sera were 
low, as might be expected from the fact that such sera are 
hypocomplementemic andfunctionally complement deficient. 
However, these sera generated high levels of TCC during in- 
cubation with adipocytes, and the level of TCC correlated 
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Figure 4. LDH activity (delta LDH) with time in infranatants from 
incubations ofadipocytes with NeF sera lone and with the addition of 
10 mM EDTA or 200 #g/ml of anti-D antibody. 
closely with the level of LDH, a marker of cell lysis. The 
slopes of the regression lines (Fig. 3) for the two NeF sera 
were virtually identical, suggesting that the relationship be- 
tween LDH release and TCC generation was very similar 
for these two sera. With control sera, by contrast, although 
some TCC was generated, the consequences were different 
since there was no adipocyte lysis. Maximal TCC generation 
with zymosan did not lead to cell lysis. IgG preparations, 
which retained NeF activity, had a similar effect to whole 
sera, indicating that the lytic activity was contained in the 
IgG portion. Blockade of the complement system by EDTA 
abolished the effect, and a mAb which blocks the function 
of factor D, reduced the amount of cell lysis. Thus NeF- 
containing sera have the potential to cause complement- 
mediated fat cell damage via the alternative pathway. 
The production of factor D, factor B, and C3 by adipo- 
cytes (7-9) and the capacity of these cells to activate the al- 
ternative pathway of complement (9) indicate a previously 
unsuspected role for the alternative pathway of complement 
in normal regulation of adipose tissue. Factor D/adipsin ex- 
pression is increased in fasting states and decreased in certain 
animal models of obesity (7, 16). Adipocytes from obese 
animals are less able to activate the alternative pathway in 
vitro and in vivo (9). Previously, factor D was thought to 
be solely produced by cells of the monocyte/macrophage lin- 
eage, but it is now apparent hat adipose tissue is a major 
site of factor D production in rodents (7) and in humans (8). 
Deficiency of factor D in humans is rare. Such individuals 
are not obese (17), so that clearly other mechanisms of adi- 
pose tissue regulation must exist. 
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Improved understanding ofregulatory mechanisms in adi- 
pose tissue has obvious wide-ranging implications. The com- 
plement system, and particularly the alternative pathway, may 
play a physiological role in adipocyte biology. Our data pro- 
vide an illustration of the consequences of deregulation i  
humans. Whether complement-mediated adipocyte lysis could 
be engaged for therapeutic benefit in obesity remains highly 
speculative, but is an attractive possibility. Antibodies to adipo- 
cytes have been widely tested in animals, with the aim of 
producing lean animals. This is particularly effective in the 
rat, where antiadipocyte antibodies reduce body fat by comple- 
ment-mediated a ipocyte lysis (18). The loss of fat tissue in 
such animals seems to be permanent. The metabolic onse- 
quences of this are largely unknown. Fat cell loss in PLD 
in human is also permanent, suggesting that, as in the an- 
imal studies, once adipocytes are lost, they are not replaced. 
It remains unclear why adipocyte loss in PLD is localized 
to the upper body, and why adipose tissue is lost suddenly 
and in only a proportion of NeF-positive individuals. There 
may be regional and/or individual differences in the expres- 
sion of complement components and/or regulatory proteins 
by adipocytes. The association between the onset of PLD and 
recent viral infection could be explained by an increase in vas- 
cular permeability and enhanced access of NeF to the vicinity 
of the adipocyte, although this would require the phenomenon 
to be extremely sensitive to NeF concentration. Perhaps more 
likely is an effect of increased levels of certain cytokines during 
interment infection: alternative pathway activation by adipo- 
cytes is enhanced by IL-1 and TNF-c~ (9). Further study of 
adipocyte lysis by NeF sera should enable testing of these hy- 
potheses. 
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